Schuyler LLC – Trademark Portfolio
Entity Type: 16
Schuyler LLC holds 11 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 5 (Pharmaceuticals) — 8 filings in this category. The portfolio also extends into Class 41 (Education & Entertainment) across 4 Nice Classification classes. Currently, 6 trademarks are registered. Notable registered marks include RELIFOR, RESORTIN, FUTUREVET, GLENHAVEN, and REJUVENATE. The owner is based in Portland, OR.
8000 NE Tillamook Street
Portland, OR 97213
Showing of trademarks Trademarks
Trademark Classifications
Schuyler LLC's trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Education; providing of training; entertainment; sporting and cultural activities
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Frequently Asked Questions
How many trademarks does Schuyler LLC have?
Schuyler LLC has 11 U.S. trademarks filed with the USPTO. Of these, 6 registered, 2 abandoned, 3 cancelled.
What trademark classes does Schuyler LLC file in?
Schuyler LLC files trademarks across 4 Nice Classification classes. The most active classes are Class 5 (Pharmaceuticals), Class 41 (Education & Entertainment), Class 10 (Medical Apparatus), Class 44 (Medical Services). Class 5 covers pharmaceutical and veterinary preparations; sanitary preparations for medical purposes.
What are Schuyler LLC's most well-known trademarks?
Schuyler LLC's registered trademark portfolio includes well-known marks such as RELIFOR, RESORTIN, FUTUREVET, GLENHAVEN, and REJUVENATE. These are among 6 currently registered trademarks in the portfolio.
What is Schuyler LLC's trademark registration success rate?
Schuyler LLC has a 55% trademark registration rate, with 6 out of 11 resolved applications resulting in successful registration. Currently, 0 applications are pending review.